Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Touchstone Balanced Fund Western & Southern Financial Group / Touchstone Investments | “Equity changes included exiting SS&C Technologies Holdings, Inc. (Industrials sector) and Goldman Sachs Group, Inc. (Financials sector) while initiating positions in QXO, Inc. (Industrials sector), SAP SE (IT sector), Blackstone, Inc. (Financials sector), and Cencora, Inc. (Health Care sector).” | NEUTRAL | Q2 2026 Jul 30, 2026 | View Pitch |
Alpha Wealth Funds - The Insiders Fund Portfolio Manager | “Cencora, formerly known as AmerisourceBergen, is a top-tier global pharmaceutical solutions leader and a top 10 Fortune 500 company. Generating over $300 billion in annual revenue, Cencora anchors the global healthcare supply chain by facilitating secure, reliable distribution of pharmaceuticals and health products. The company partners with manufacturers, care providers, and pharmacies across the value chain to optimize market access to critical medical therapies. Cencora recently expanded its clinical reach by completing the major acquisition of OneOncology, boosting its specialized U.S. Healthcare Solutions infrastructure. A near monopoly in pharmaceutical distribution and a keyway to play healthcare in a value-oriented name. Cencora is a high-quality healthcare distributor with a mission-critical role in the pharmaceutical supply chain. Demand is driven by aging demographics, rising specialty drug usage, and resilient healthcare spending rather than economic cycles. The company generates strong free cash flow, consistently buys back shares, and has a long runway from high-margin specialty pharmaceuticals and oncology distribution. Scale creates competitive advantages and customer stickiness, while valuation remains reasonable versus its earnings growth. It isn't flashy, but it compounds capital steadily—exactly the type of business that can outperform over long periods by quietly benefiting from healthcare's secular growth and the expected efficiency and scientific gains from AI.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Latitude Global Fund Freddie Lait | “In May, Cencora reported earnings. The company has generated fundamental value growth (earnings per share + dividends) of 15% per year for the past five and ten years, and our research suggests this w” | NEUTRAL | Q2 2026 Jul 13, 2026 | View Pitch |
Bell Global Emerging Companies Fund Ned Bell, Joel Connell, Matt Saddington | “Other laggards included Cencora (Health Care). The stock detracted from performance amid sector-level weakness. No material company-specific issues were cited during the period. The company remains a critical intermediary in pharmaceutical distribution with scale advantages. Performance weakness reflects broader health care sentiment rather than fundamentals. BSD Analysis: Cencora sits at the least glamorous but most powerful junction in healthcare: drug distribution and specialty services. Margins are thin by design, but scale turns volume into massive, reliable cash flow. Specialty pharma and oncology distribution add higher-quality growth on top of the utility core. Regulatory scrutiny never disappears, but it usually entrenches incumbents rather than disrupts them. Switching costs are systemic — pharmacies and manufacturers can't easily bypass distributors. Capital allocation has improved, with buybacks doing real work. Earnings volatility looks scarier than the underlying economics. This is not a healthcare innovation story. It's healthcare infrastructure that quietly compounds.” | BULL | Q4 2025 Nov 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
